

MyPEAK-1 Phase 1b/2 clinical trial design



Study Objectives

- Safety, tolerability
- Dose-finding
- Pharmacodynamics

Design

- Open-label, multi-center, dose-escalation and dose-expansion
- 52-week trial period with four-year safety and efficacy follow-up
- Cardiac biopsies at baseline, post-dose and ~52 weeks (effective with Cohort 1, patient 3)

